Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 13/20 | 0.51 |
| ▸ | F13A1 | P00488 | 10/20 | 0.51 |
| ▸ | TGM1 | P22735 | 7/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16906776 | 0.87 | TGM2 (0.52) | TGM2F13A1TGM1KDM4EHSD17B10 | |
| SCHEMBL16906771 | 0.82 | TGM2 (0.53) | TGM2F13A1TGM1GPR119TGM3 | |
| SCHEMBL19914349 | 0.78 | MAP4K4 (0.51) | MAP4K4GPR119PIK3CA | |
| SCHEMBL998820 | 0.76 | HTT (0.51) | POLB | |
| SCHEMBL25085726 | 0.76 | TGM2 (0.64) | TGM2F13A1TGM1GPR119 | |
| SCHEMBL1348953 | 0.76 | POLB (0.72) | TGM2F13A1TGM1HSD17B10POLB | |
| SCHEMBL29057519 | 0.75 | MAP4K4 (0.43) | MAP4K4GPR119POLB | |
| SCHEMBL856502 | 0.74 | HSD17B10 (0.76) | TGM2F13A1TGM1KDM4EHSD17B10 | |
| SCHEMBL3897024 | 0.74 | KDM4E (0.52) | KDM4EHSD17B10GPR119 | |
| SCHEMBL16781 | 0.74 | PKM (0.71) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556202-B2 | Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug | MERCK SHARP & DOHME CORP. (US) | 2017-01-31 | — | — | US | disclosed |
| EP-2867220-B1 | SULFONAMIDE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20150197531-A1 | SULFONAMIDE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME CORP. (US) | 2015-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197531-A1 | SULFONAMIDE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | SULT2A1, SULT1A1, SULT1E1 | TGM2 3285/4885F13A1 1221/4885TGM1 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.